CVM Stock Quote and Technical Analysis
| Portfolios | Markets | Resources |
|
|
|
Cel-Sci Corporation (CVM) ► 0.241 (0.00) Open: N/A High: N/A Low: N/A Afterhours: N/A - N/A Volume: 0 6/18/2013 4:00pm |
Interactive Chart |
| EPS: -0.045 (Current Year Estimated: -0.04) Dividend: N/A P/E: N/A Technicals: 52 Week Range: 0.21 - 0.47 50 Day Moving Average: 0.2563 200 Day Moving Average: 0.2585 Pivot Point: Not Available Login or signup free to Add "CVM" to your portfolio Resources: |
| News: CEL-SCI Corporation To Present At The Second Annual Marcum LLP MicroCap Conference Thu, 23 May 2013 12:00:00 GMT [PR Newswire] - VIENNA, Va., May 23, 2013 /PRNewswire/ -- CEL-SCI Corporation (NYSE MKT: CVM) announced today that Geert Kersten, Chief Executive Officer, will present at the Second Annual Marcum LLP MicroCap Conference ... CEL SCI CORP Financials Fri, 17 May 2013 17:04:39 GMT CEL-SCI Corporation Reports Second Quarter 2013 Financial Results Fri, 10 May 2013 20:35:00 GMT [Business Wire] - CEL-SCI Corporation reports financial results for the fiscal quarter ended March 31, 2013. CEL SCI CORP Files SEC form 10-Q, Quarterly Report Fri, 10 May 2013 13:31:07 GMT CEL-SCI presents data on LEAPS vaccine Mon, 06 May 2013 12:34:36 GMT CEL-SCI Presents Data Showing LEAPS Vaccine is Successful in Reducing Rheumatoid Arthritis Index Score in a Second Animal Model Mon, 06 May 2013 12:30:00 GMT [Business Wire] - CEL-SCI Corporation today announced results from a recently completed efficacy study in a second animal model of rheumatoid arthritis using the LEAPS technology , which demonstrates that LEAPS has the potential for use as a therapeutic vaccine to treat different types of RA, each of which possesses different disease characteristics. NEW STORY CEL-SCI to Present at the American Association of Immunologists 100th Annual Meeting on Saturday May 4th Fri, 03 May 2013 14:55:05 GMT [at noodls] - CEL-SCI TO PRESENT AT THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS 100TH ANNUAL MEETING ON SATURDAY MAY 4TH Vienna, VA, May 3, 2013 -- CEL-SCI Corporation (NYSE MKT: CVM) announced today that it will deliver ... CEL-SCI To Present at the American Association of Immunologists 100th Annual Meeting on Saturday May 4th Fri, 03 May 2013 13:11:00 GMT [Business Wire] - CEL-SCI Corporation announced today that it will deliver a presentation at the American Association of Immunologists 100th Annual Meeting at the Hawaii Convention Center in Honolulu, Hawaii. Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail! Fri, 26 Apr 2013 12:15:00 GMT Bullish $10 Million Bet Placed by CRO After CEL-SCI Acts to Accelerate Phase III Enrollment Wed, 24 Apr 2013 11:01:00 GMT [Marketwired] - In newly published news, CEL-SCI Corporation has provided investors a much needed update on the Phase III Clinical Trial of its investigational drug Multikine. CEL-SCI provides update on phase III clinical trial of Multikine Tue, 23 Apr 2013 12:05:00 GMT CEL-SCI Corporation Provides Update on Phase III Clinical Trial Tue, 23 Apr 2013 12:00:00 GMT [Business Wire] - CEL-SCI Corporation today provided an update on the Phase III Clinical Trial of its investigational drug Multikine* for the treatment of head and neck cancer. Three Biotech Stocks With Low Price But Great Potential Tue, 16 Apr 2013 10:17:19 GMT BioCryst Won't Profit From Bird Flu Outbreak in China Mon, 08 Apr 2013 19:11:00 GMT CEL-SCI Corporation Announces That NIAID Collaborators Have Submitted Bird Flu Study for Publication to Prestigious Scientific Journal Mon, 08 Apr 2013 16:55:00 GMT [Business Wire] - CEL-SCI Corporation today announced that its collaborators at the National Institute of Allergy and Infectious Diseases , part of the National Institutes of Health, USA, have submitted for publication to a prestigious scientific journal the results from efficacy studies in animals of L.E.A.P.S. CEL-SCI's Price Rebound Looks Strong Thu, 04 Apr 2013 11:01:00 GMT [Marketwired] - Anyone who has ever had a family member or friend afflicted with cancer knows first hand that the treatments they must endure seem far more devastating than the disease itself. An exciting video released ... CEL-SCI Corporation Releases New Video on Its Website Tue, 02 Apr 2013 12:00:00 GMT [Business Wire] - CEL-SCI Corporation announced today that it has released a new video about its investigational cancer drug Multikine* and the dedicated manufacturing facility to produce Multikine near Baltimore, MD, USA. Cel-Sci Corp CEO Buys More Than 348K Shares and 4 Insider Trades to Note Thu, 28 Mar 2013 13:15:09 GMT Taglich Brothers Initiates Coverage on CEL-SCI Corporation Mon, 04 Mar 2013 18:39:20 GMT [Marketwired] - Taglich Brothers, Inc. announces it initiated coverage of CEL-SCI Corporation. CEL-SCI Announces Initiation of New Sites for Multikine Phase III Clinical Study for Head and Neck Cancer in Taiwan Mon, 25 Feb 2013 15:00:00 GMT [Business Wire] - CEL-SCI Corporation announced today that its Taiwanese partner, Orient Europharma, has added two additional Taiwanese clinical centers in CEL-SCI’s Phase III head and neck cancer clinical trial for Multikine® , the Company’s flagship investigational immunotherapy. All Company News is Powered by Yahoo! Finance |
All Discover Card holders who did NOT call in and switch to the new Discover IT Card. You may be receiving less than you should be on your cash back. According to the folks working the Discover IT...
Discover